Priority,Rule
Very High (AA)​,"GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC, ground-breaking data, high-quality ISS from key competitors or other competitors of interest that may change the SoC (GSK or competitor sponsored, well-known academic center, multiple academic centers, consortiums, key indication/s of interest) ​
GSK- or key competitor–sponsored symposia in indication/s of interest ​Session type considerations 
Secondary condition: LBA/Oral presentation that will be part of a presidential or highlighted as a news of the day, by the congress​
Only Oral presentations will be considered ​"
High (A)​,"Company-sponsored pivotal trials (usually ph 3, 2) from other competitors of interest​
High-quality RWE/HEOR studies from key competitors or competitors that may change the SoC (large database, indication of interest, potential to change SoC, or inform a study that can change SoC) ​
ISS from key competitors or other competitors of interest [well-known academic center, indication of interest, multiple academic centers (>20), consortiums] ​
GSK- or key competitor–sponsored medical education sessions on indications of interest ​
Any pivotal/ground-breaking company-sponsored ph 1 datasets from key competitors (assets that have not had a pivotal data readout or assets going into rare indications)​
Session type considerations ​
Oral presentations​
Poster/e-poster presentations to be considered only when it fulfils any of the above criteria         "
Medium (B)​,"Non-pivotal studies from key competitors ​
Single-center, single-country datasets from key competitors and other emerging competitors of interest​
Any abstract with clinical data which do not fall under Very High/High criteria​
Session type considerations ​
Oral presentations​
Poster or e-poster presentations​
Trials in progress (TIP)​"
Low (C)​,Non-clinical/pre-clinical studies from key competitors or other competitors of interest ​
Internal​,"GSK-sponsored relevant abstracts (with indication of interest and keywords) excluding GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC or GSK sponsored symposia or medical education session - as they are considered as Very High/High​"
